TMED9: a potential therapeutic target and prognostic marker in glioma and its implications across pan-cancer contexts
Our comprehensive analysis positions TMED9 as a critical player in cancer progression and immune modulation, especially in gliomas. Elevated TMED9 expression correlates with poorer outcomes and may serve as a prognostic marker and therapeutic target. Future research should focus on elucidating TMED9's mechanistic pathways and validating its role in clinical settings to enhance glioma treatment strategies.
Authors
- Bobin Mi (ORCID: https://orcid.org/0000-0002-6994-4363)
- Chaolin Li (ORCID: https://orcid.org/0000-0002-7308-5493)
Institutions
- Maternal and Child Health Hospital of Sichuan Province (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1558881
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52